Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombolysis in Factor Xa-inhibitors Trial (SIFT)
2023-509907-34-01Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised trial of tissue-plasminogen activator and tenecteplase in ischemic stroke, sponsored by Oslo University Hospital. Primary endpoint: Early neurological improvement. Planned start Mar 2025; status: authorised.
02
Drugs
tissue-plasminogen activatortenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2023-509907-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509907-34-01.